STOCKHOLM, Dec. 29, 2025 /PRNewswire/ -- Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, registrational Phase 3 DIAGNODE-3 trial in type 1 diabetes from 24 to 15 months, per FDA guidance, enabling the full primary efficacy readout of the trial to occur nine months earlier than previously planned and communicated. The previously announced interim efficacy readout, involving approximately 170 p

SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology platform that covers this end-to-end modality range, supporting programs from in vitro ADME assays through in vivo PK and efficacy studies. Adventures in DMPK: From Small Molecules and PROTACs to Peptides a

TAIPEI and SAN DIEGO, Dec. 28, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. (TPEx: 6492, hereafter "Senhwa"), today announced another major milestone. The Company's first-in-class investigational drug Pidnarulex (CX-5461) will be evaluated in combination with the globally recogn

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of

SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for its allogeneic BCMA-targeted CAR-T cell therapy product, CT0596. The applications seek to initiate two corresponding Phase Ib/Ⅱ clinical trials for the treatment of relapsed/refractory m

Your support is helping move important science forward. Give today to sustain our critical research. Dear ALS Community, Earlier this month, at the International Symposium on ALS/MND, I watched a presentation from AL-S Pharma announcing that AP-101—a therapeutic antibody targeting misfolded SOD1—had succeeded in Phase 2b and is now advancing toward Phase 3 clinical trials. Our team at ALS TDI helped make that molecule what it is. Years ago, we partnered with a European biotech called Neurimmune

Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, registrational Phase 3 DIAGNODE-3 trial in type 1 diabetes from 24 to 15 months, per FDA guidance, enabling the full primary efficacy readout of the trial to occur nine months earlier than previously planned and communicated. The previously announced interim efficacy readout, involving approximately 170 participants with 15-month data, remains o

Skin substitutes are an inappropriate treatment option in long-term care because they can be harmful to residents & an inferior choice clinically & financially In long-term care, skin substitutes are a poor choice clinically & financially. A preferred treatment is a wound dressing program, which is easy to implement & has greater healing success potential.” — David Navazio - President & CEO, Gentell, Inc. YARDLEY, PA, UNITED STATES, December 28, 2025 / EINPresswire.com / -- Skin substitutes have

RIYADH, SAUDI ARABIA, December 28, 2025 / EINPresswire.com / -- At King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh, artificial intelligence enabled brain implants are used as part of advanced care for patients with neurological conditions, including Parkinson’s disease and selected movement disorders. The implant functions by continuously analyzing brain signals and responding to abnormal activity through targeted electrical stimulation. This adaptive approach allows treatme

ٍٍRIYADH, SAUDI ARABIA, December 28, 2025 / EINPresswire.com / -- At King Faisal Specialist Hospital & Research Centre, genomic testing is increasingly used when conventional diagnostics fail to provide clear answers. Patients referred to the hospital often present with rare diseases, inherited conditions, or medically complex cases that require deeper molecular analysis to support clinical decision making. Whole genome sequencing is applied across several programs, particularly in pediatrics an